Renal sympathetic denervation and renal physiology

Current Clinical Pharmacology

Volumn 8, Issue 3, 2013, Pages 189-196

  Kalaitzidis, Rigas G ^a   Karasavvidou, Despina ^a   Siamopoulos, Kostas C ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Hypertension; Renal physiology; Renal sympathetic denervation

Indexed keywords

ADRENERGIC SYSTEM; ARTICLE; BLOOD PRESSURE REGULATION; EFFERENT NERVE; ESSENTIAL HYPERTENSION; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY DENERVATION; KIDNEY FUNCTION; KIDNEY ISCHEMIA; KIDNEY NERVE; KIDNEY VASCULAR RESISTANCE; PATHOGENESIS; PRIORITY JOURNAL; RENIN RELEASE; SENSORY NERVE; SYMPATHETIC NERVE; WAKEFULNESS;

ANIMALS; BLOOD PRESSURE; CATHETER ABLATION; HUMANS; HYPERTENSION; KIDNEY; NEURONS, AFFERENT; RENAL INSUFFICIENCY, CHRONIC; SYMPATHECTOMY; SYMPATHETIC NERVOUS SYSTEM; TIME FACTORS;

EID: 84882781008     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574884711308030004     Document Type: Article

References (57)

1. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-1281.
2. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997; 77(1): 75-197.
3. Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage Hypertension 1999; 34(4): 724-728.
4. Bernard C. LećEons sur les Propriétés et les Altérations Pathologiques des Liquides de L'Organisme. Bailliére et Fils 1859(2): 170-171.
5. Starling EH. The Chemical Control of the Body. Harvey Lectures 1907-1908. New York: Lippincott, 1909; 115-31.
6. Muller JB. Electron microscopic and histochemical evidence for a tubular innervation in the renal cortex of the monkey J Ultrastruct Res 1972; 41: 533-549.
7. Evelyn KA, Singh MM, Chapman WP, et al. Effect of thoracolumbar sympathectomy on the clinical course of primary (essential) hypertension. A ten-year study of 100 sympathectomized patients compared with individually matched, symptomatically treated control subjects. Am J Med 1960; 28: 188-221.
8. Morrissey DM, Brookes VS, Cooke WT. Sympathectomy in the treatment of hypertension; review of 122 cases. Lancet 1953; 1403-408.
9. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc 1953; 152(16): 1501-1504.
10. Grimson KS, Orgain ES, Anderson B, D'Angelo GJ. Total thoracic and partial to total lumbar sympathectomy, splanchnicectomy and celiac ganglionectomy for hypertension. Ann Surg 1953; 138(4): 532-547.
11. Barajas L, Liu L, Powers K. Anatomy of the renal innervation: intrarenal aspects and ganglia of origin. Can J Physiol Pharmacol 1992; 70(5):735-749.
12. Ditting T, Freisinger W, Siegel K, et al. Tonic postganglionic sympathetic inhibition induced by afferent renal nerves?, Hypertension 2012; 59(2): 467-476.
13. DiBona GF. Sympathetic nervous system and the kidney in hypertension. Curr Opin Nephrol Hypertens 2002; 11(2): 197-200.
14. Kirchheim H, Ehmke H, Persson P. Sympathetic modulation of renal hemodynamics, renin release and sodium excretion. Klin Wochenschr 1989; 67(17): 858-864.
15. DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol 2010; 298(2): 245-253.
16. Bell-Reuss E, Trevino DL, Gottschalk CW. Effect of renal sympathetic nerve stimulation on proximal water and sodium reabsorption. J Clin Invest 1976; 57(4): 1104-1107.
17. Holmer S, Rinne B, Eckardt KU, et al. Role of renal nerves for the expression of renin in adult rat kidney. Am J Physiol 1994; 266(5): 738-745.
18. Schultz HD, Li YL, Ding Y. Arterial chemoreceptors and sympathetic nerve activity: implications for hypertension and heart failure. Hypertension 2007; 50(1): 6-13.
19. Zucker IH. Novel mechanisms of sympathetic regulation in chronic heart failure. Hypertension 2006; 48(6): 1005-1011.
20. Perlini S, Palladini G, Ferrero, I, et al. Sympathectomy or doxazosin, but not propranolol, blunt myocardial interstitial fibrosis in pressure-overload hypertrophy. Hypertension 2005; 46 (5): 1213-1218.
21. Brandt MC, Mahfoud F, Reda S, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 2012; 59(10): 901-909.
22. Kopp UC, Cicha MZ, Smith LA, et al. Renal sympathetic nerve activity modulates afferent renal nerve activity by PGE2-dependent activation of alpha1-and alpha2-adrenoceptors on renal sensory nerve fibers. Am J Physiol Regul Integr Comp Physiol 2007; 293(4): 1561-1572.
23. Kon V. Neural control of renal circulation. Miner Electrolyte Metab 1989; 15(1-2): 33-43.
24. Katholi RE, Carey RM, Ayers CR, et al. Production of sustained hypertension by chronic intrarenal norepinephrine infusion in conscious dogs. Circ Res 1977; 40(5): 118-126.
25. Converse RL Jr, Jacobsen TN, Jost CM, et al. Paradoxical withdrawal of reflex vasoconstriction as a cause of hemodialysisinduced hypotension. J Clin Invest 1992; 90(5): 1657-1665.
26. Esler M, Jennings G, Lambert G. Noradrenaline release and the pathophysiology of primary human hypertension. Am J Hypertens 1989; 2(3): 140-146.
27. Schlaich MP, Lambert E, Kaye DM, et al. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation. Hypertension 2004; 43(2): 169-175.
28. Felder RB, Heesch CM, Thames MD. Reflex modulation of carotid sinus baroreceptor activity in the dog. Am J Physiol 1983; 244(3): 437-443.
29. Kopp UC, Smith LA, DiBona GF. Renorenal reflexes: neural components of ipsilateral and contralateral renal responses. Am J Physiol 1985; 249(4): 507-517.
30. Katholi RE, Whitlow PL, Hageman GR, Woods WT. Intrarenal adenosine produces hypertension by activating the sympathetic nervous system via the renal nerves in the dog. J Hypertens 1984; 2(4): 349-359.
31. Katholi RE, Hageman GR, Whitlow PL, Woods WT. Hemodynamic and afferent renal nerve responses to intrarenal adenosine in the dog. Hypertension 1983; 5(2): 149-154.
32. Grassi G, Seravalle G, Quarti-Trevano F, et al. Adrenergic, metabolic, and reflex abnormalities in reverse and extreme dipper hypertensives. Hypertension 2008; 52(5): 925-931.
33. Siddiqi L, Joles JA, Grassi G, Blankestijn PJ. Is kidney ischemia the central mechanism in parallel activation of the renin and sympathetic system? J Hypertens 2009; 27: 1341-1349.
34. Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease. Nephrol Dial Transplant 2004; 19(6): 1354-1357.
35. Miyajima E, Yamada Y, Yoshida Y, et al. Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension 1991; 17(6): 1057-1062.
36. Zhang ZH, Yu Y, Kang YM, et al. Aldosterone acts centrally to increase brain renin-angiotensin system activity and oxidative stress in normal rats. Am J Physiol Heart Circ Physiol 2008; 294(2): 1067-1074.
37. Cutler JA, Sorlie PD, Wolz M, et al. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008; 52(5): 818-827.
38. Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol 2008; 52(22): 1749-1757.
39. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research Circulation 2008; 117(25): 510-526.
40. Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011; 123(18): 1940-1946.
41. Witkowski A, Prejbisz A, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011; 58(4): 559-565.
42. Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomized controlled trial. Lancet 2010; 376(9756): 1903-1909.
43. Friedman O, Bradley TD, Chan CT, et al. Relationship between overnight rostral fluid shift and obstructive sleep apnea in drugresistant hypertension. Hypertension 2010; 56 (6): 1077-1082.
44. Bombelli M, Facchetti R, Carugo S, et al. Left ventricular hypertrophy increases cardiovascular risk independently of inoffice and out-of-office blood pressure values. J Hypertens 2009; 27(12): 2458-2464.
45. Pierdomenico SD, Cuccurullo F. Risk reduction after regression of echocardiographic left ventricular hypertrophy in hypertension: a meta-analysis. Am J Hypertens 2010; 23(8): 876-881.
46. Grassi G, Dell'Oro R, Quarti-Trevano F, et al. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia 2005; 48 (7): 1359-1365.
47. Grassi G, Dell'Oro R, Facchini A, et al. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens 2004; 22(12): 2363-2369.
48. Krum H, Sobotka P, Mahfoud F, Bohm M, Esler M, Schlaich M. Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system. Circulation 2011; 123: 209-15.
49. Grassi G, Seravalle G, Dell'Oro R, Mancia G. Sympathetic mechanisms, organ damage, and antihypertensive treatment. Curr Hypertens Rep 2011; 13: 303-8.
50. Lakhanpal JR, Domanski MJ. Hypothesis: Catheter-based renal sympathetic denervation should be the initial therapy for essential hypertension. Med Hypotheses 2012; 78: 482-84.
51. Katholi RE, Rocha-Singh KJ, Goswami NJ, Sobotka PA. Renal nerves in the maintenance of hypertension: a potential therapeutic target. Curr Hypertens Rep 2010; 12: 196-204.
52. Schlaich MP, Sobotka PA, Krum H, et al. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension 2009; 54: 1195-1201.
53. Hausberg M, Kosch M, Harmelink P, et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106: 1974-79.
54. Grassi G, Quarti-Trevano F, Seravalle G, et al. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension 2011; 57: 846-51.
55. Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105: 1354-59.
56. Mallamaci F, Tripepi G, Maas R, et al. Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J Am Soc Nephrol 2004; 15: 435-41.
57. Hausberg M, Grassi G. Mechanisms of sympathetic overactivity in patients with chronic renal failure: a role for chemoreflex activation? J Hypertens 2007; 25: 47-9.